DSEN Research

The searchable table below lists active and completed DSEN queries by topic, scope and team. Links to study protocols, brief research abstracts summarizing the results, and to scientific publications are included as they become available.

Legend:

  • CAN-AIM: the Canadian Network for Advanced Interdisciplinary Methods for Comparative Effectiveness Research
  • CCNMA: The Canadian Collaboration for Drug Safety, Effectiveness and Network Meta-Analysis
  • CNODES: the Canadian Network for Observational Drug Effect Studies
  • DEMO: Demonstration Project
  • KSRU: Knowledge Synthesis Research Unit
  • MAGIC: the Methods and Applications Group for Indirect Comparisons
  • NETMAN: Network Meta-Analysis Team
  • PREVENT: Pharmacogenomics of Adverse Events National Team
  • SEARCH: Active Surveillance and Evaluation of Adverse reactions in Canadian Healthcare

As of October 8th, 2014, the KSRU, NETMAN and CCMNA teams now form the MAGIC team. As of April 1st, 2018, SEARCH and PREVENT teams now form the SEARCH & PREVENT team.

# Topic Scope Team Status
Demo 1 Proton pump inhibitors and community-acquired pneumonia Safety CNODES Completed
2013-07
Demo 2 High-dose statins and risk of acute kidney injury Safety CNODES Completed
2012-01
Demo 3 Anti-tumor necrosis factor agents versus disease-modifying anti-rheumatic drugs in reducing orthopedic surgery in rheumatoid arthritis Safety CAN-AIM Completed
2015-10
Demo 4 Pharmacogenomic markers of anthracycline‐induced heart failure in children Safety PREVENT Completed
2015-02
Demo 5 Pharmacogenomic predictors of statin‐induced myopathy Safety PREVENT Completed
2013-09
Demo 6 Inhaled corticosteroid use in children and in pregnancy Safety SEARCH Completed
Demo 7 Cognitive enhancers for Alzheimer dementia and mild cognitive impairment Safety KSRU Completed
2013-09
Demo 8 Additive treatment effects in multiple treatment comparison meta-analysis Effectiveness NETMAN Completed
2012-06
Q10-03 Proton pump inhibitors and myocardial infarction Safety CNODES Completed
2012-01
Q10-04 Atypical antipsychotics and breast cancer Safety CNODES Completed
2012-01
Q10-11 5-HT3 antagonists and cardiac safety Safety KSRU Completed
2013-12
Q10-11 5-HT3 antagonists and cardiac safety Safety SEARCH Completed
Q10-12 Atypical antipsychotics and diabetic ketoacidosis Safety CNODES Completed
2013-02
Q10-18 Proton pump inhibitors and clostridium difficile-associated diarrhea Safety CNODES Completed
2012-01
Q10-22b Disease-modifying anti-rheumatic drugs in ankylosing spondylitis Safety CAN-AIM Completed
2015-09
Q10-22c Atrial fibrillation related-hospitalizations Safety CNODES Completed
2012-07
Q10-23 Isotretinoin-related congenital malformations Safety CNODES Completed
Q11-01 Direct oral anticoagulants for anticoagulation in atrial fibrillation Safety & Effectiveness CCNMA Completed
2012-04
Q11-03 Therapies for hypertension in non-diabetic patients Safety & Effectiveness NETMAN Completed
2012-10
Q11-03 Therapies for hypertension in non-diabetic patients Safety & Effectiveness CAN-AIM Completed
2015-04
Q11-04 Long-acting versus intermediate-acting insulin for type 1 diabetes Safety & Effectiveness KSRU Completed
2013-12
Q11-04 Long-acting versus intermediate-acting insulin for type 1 diabetes Safety & Effectiveness CAN-AIM Completed
2016-02
Q11-04b Sitagliptin versus intermediate-acting insulin for type 2 diabetes Safety & Effectiveness KSRU Completed
2013-10
Q11-04b Sitagliptin versus intermediate-acting insulin for type 2 diabetes Safety & Effectiveness CAN-AIM Completed
2016-02
Q11-05 Interventions for smoking cessation Safety CCNMA Completed
2014-12
Q11-06 Serotonin reuptake inhibitors and risks of fracture Safety NETMAN Completed
2014-02
Q11-06 Serotonin reuptake inhibitors and risk of fracture Safety CAN-AIM Completed
2014-01
Q11-07 Levodopa - carbidopa - entacapone and cardiovascular events Safety CCNMA Completed
2014-06
Q12-02 Statins and diabetes in post myocardial infarction patients Safety CNODES Completed
2014-05
Q12-04 Quetiapine and cardiomyopathy Safety CNODES Completed
2016-06
Q12-04T Quetiapine and acute liver injury Safety CNODES Completed
2016-07
Q12-05 Levetiracetam and developmental toxicity Safety KSRU Completed
2016-11
Q12-07 Elevated prolactin levels in pediatric patients exposed to atypical antipsychotics Safety NETMAN Completed
2015-06
Q12-08 Selective serotonin and norepinephrine-reuptake inhibitors and renal failure Safety CNODES Completed
2013-12
Q12-10 Newer antidepressants and persistent pulmonary hypertension of the newborn Safety CNODES Ongoing
Q12-10 Newer antidepressants and persistent pulmonary hypertension of the newborn Safety CAN-AIM Completed
2015-01
Q13-01 Darunavir and congenital malformations Safety KSRU Completed
2015-04
Q13-01 Darunavir and congenital malformations Safety CAN-AIM Completed
2015-02
Q13-02 Domperidone and Parkinson's disease Safety CNODES Completed
2015-07
Q13-03 Safety of opioids Safety CNODES Completed
2018-05
Q13-05 Optimizing chronic hepatitis C treatment Safety & Effectiveness SEARCH & PREVENT Ongoing
Q13-06 Incretin-based therapies and pancreatitis and/or pancreatic cancer Safety CNODES Completed
2015-07
Q13-4T Incretin-based therapies and heart failure Safety CNODES Completed
Q14-01 Pharmacological treatments for rheumatoid arthritis Safety & Effectiveness CCNMA Completed
2018-04
Q14-01 Pharmacological treatments for rheumatoid arthritis Safety & Effectiveness CNODES Ongoing
Q14-02 Direct oral anticoagulants for the treatment of  venous thromboembolic events Safety & Effectiveness CCNMA Completed
2016-02
Q14-02b Direct oral anticoagulants for the treatment of  venous thromboembolic events Safety & Effectiveness CNODES Completed
2016-12
Q14-02b Direct oral anticoagulants for the treatment of  venous thromboembolic events Safety & Effectiveness SEARCH Ongoing
Q14-02b Direct oral anticoagulants for the treatment of  venous thromboembolic events Safety & Effectiveness PREVENT Ongoing
Q14-02c Direct oral anticoagulants for the prevention of  venous thromboembolic events in the hospital setting Safety & Effectiveness MAGIC Completed
Q14-05 Efficacy of modified released methylphenidate linked to pharmacokinetic profile Efficacy CCNMA Completed
Q15-01 Drugs for chronic Hepatitis C Safety & Effectiveness MAGIC Completed
Q15-04 Dual antiplatelet therapy following percutaneous coronary intervention Effectiveness MAGIC Completed
Q15-04T Cognitive enhancers for treating Alzheimer dementia Safety MAGIC Completed
2016-06
Q15-06 Anti–vascular endothelial growth factor drugs for retinal conditions Effectiveness MAGIC Completed
2016-05
Q15-07 Treatments for latent tuberculosis infection Safety MAGIC Completed
2016-03
Q15-08 Conditioning regimens for allogeneic hematopoietic cell transplantation Safety & Effectiveness MAGIC Completed
2016-12
Q15-09 Prevention and treatment of graft versus host disease after allogeneic hematopoietic cell transplantation Safety & Effectiveness MAGIC Completed
2016-12
Q15-10 Infection management and allogeneic hematopoietic cell transplantation Safety & Effectiveness MAGIC Completed
2016-12
Q15-11 Intravitreal bevacizumab for retinal conditions Safety CAN-AIM Ongoing
Q15-14 New drugs for type 2 diabetes Effectiveness MAGIC Ongoing
Q16-01 Utilization of social media for Canadian pharmacovigilance Safety MAGIC Completed
2017-04
Q16-01 Utilization of social media for Canadian pharmacovigilance Safety CAN-AIM Ongoing
Q16-02 Use of systemic oral fluoroquinolones Safety CNODES Completed
Q16-03 Preventable adverse drug reactions as percentage of total Safety MAGIC Completed
2018-04
Q16-03 Preventable adverse drug reactions as percentage of total Safety CAN-AIM Ongoing
Q16-04 Early detection of pancreatitis Contextual MAGIC Completed
2018-08
Q16-06 Crizotinib and incidence of death Safety MAGIC Completed
Q16-07 Options to support appropriate prescribing Effectiveness MAGIC Completed
Q16-07 Options to support appropriate prescribing Effectiveness CAN-AIM Completed
2017-05
Q16-08 Ondansetron and fetal abnormalities Safety CNODES Ongoing
Q16-08 Ondansetron and fetal abnormalities Safety CAN-AIM Completed
Q16-09 Low dose fluconazole and adverse pregnancy outcomes Safety CNODES Ongoing
Q16-09 Low dose fluconazole and adverse pregnancy outcomes Safety CAN-AIM Completed
2018-05
Q16-10 Domperidone and breastfeeding women Safety CNODES Ongoing
Q16-11 Appropriate use of interventions in insomnia Safety & Effectiveness MAGIC Completed
Q16-12 Herpes zoster vaccine in individuals 50 years of age or older Safety & Effectiveness MAGIC Completed
2018-05
Q16-13 Direct oral anticoagulants and atrial fibrillation Safety & Effectiveness CNODES Ongoing
Q17-01 International collaboration pilot: Direct oral anticoagulants and atrial fibrillation Safety & Effectiveness CNODES Ongoing
Q17-02 Common Data Model pilot Safety CNODES Ongoing
Q17-03 Safety of Bowel Cleansers Safety MAGIC Ongoing
Q17-03 Safety of Bowel Cleansers Safety CNODES Ongoing
Q17-04 Comparative Efficacy and Safety of Insulin Preparations and Biosimilar Insulins for Type 1 Diabetes Mellitus Safety & Comparative Effectiveness MAGIC Ongoing
Q17-05 Comparative Safety and Effectiveness of Biosimilar and Legacy Drugs Safety & Comparative Effectiveness CAN-AIM Ongoing
Q17-06 Cancer and Immunomodulators Safety MAGIC Completed
Q17-08 Appropriate Use Organizations Comparative Effectiveness MAGIC Ongoing
Q18-01 Associations between industry incentives received by healthcare professionals and impact on drug prescribing and patient outcomes Contextual MAGIC Completed
2018-06
Q18-04 Options to Support Appropriate Opioids Prescribing Contextual CAN-AIM Ongoing
Q18-06 Risk of Macrovascular Events and Heart Failure Associated Medication Used to Treat Individuals with Type 2 Diabetes Comparative Effectiveness CNODES Ongoing
Q18-09 Risk of Urinary Tract Infection Associated with Medication Used to Treat Individuals with Type 2 Diabetes Comparative Effectiveness CNODES Ongoing
Q18-10 Risk of Amputation Associated with Medication Used to Treat Individuals with Type 2 Diabetes Comparative Effectiveness CNODES Ongoing
Q18-11 Risk of Diabetic Ketoacidosis Associated with Medication Used to Treat Individuals with Type 2 Diabetes Comparative Effectiveness CNODES Ongoing
Q18-12 The benefits and harms of drugs used for treatment or prevention of osteoporosis in postmenopausal women Safety & Effectiveness MAGIC Ongoing
Q19-01 Methods, tools and guidelines for the active surveillance of health products Contextual MAGIC Ongoing
Q19-03 Active surveillance for safety and effectiveness of health products: Canadian multi-province cohorts of pregnant women and children Contextual CAN-AIM Ongoing
Q19-04 Common data model – Phase II Contextual CNODES Ongoing
Date modified: